eFFECTOR's (EFTR) tomi Cohorts Unlikely to Be Positive, Stock is a High Risk, Downgrade to Hold, Cut PT to $6.20 - Stifel
Tweet Send to a Friend
Stifel analyst Benjamin J. Burnett downgraded eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) from Hold to Buy with a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
